Porcel J, Montalban X
2a Planta EUI, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Ps. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
J Neurol Sci. 2006 Jun 15;245(1-2):177-81. doi: 10.1016/j.jns.2005.07.021. Epub 2006 May 3.
Neuropsychological impairment is a common manifestation in multiple sclerosis (MS) and is found in 40-60% of patients. The pattern of cognitive impairment in MS is characterized by difficulties in recent memory, sustained attention, executive functions and information processing speed. These cognitive deficits have a significant impact on the patients' daily activities. However, there is no specific treatment available at present for cognitive disorders in MS patients. Treatment with acetylcholinesterase inhibitors (AChEI) has shown a positive effect on cognitive functions of patients with Alzheimer's disease and other conditions such as Lewy Body dementia, subcortical vascular dementia and Parkinson's disease. In this paper we review the results from studies and clinical trials aiming to demonstrate that AChEI could be a potential treatment for cognitive disorders in MS patients. Finally, we discuss future issues to take into consideration for AChEI treatments in the context of MS.
神经心理障碍是多发性硬化症（MS）的常见表现，40%-60%的患者存在该症状。MS患者的认知障碍模式表现为近期记忆、持续注意力、执行功能和信息处理速度方面存在困难。这些认知缺陷对患者的日常活动有重大影响。然而，目前尚无针对MS患者认知障碍的特效治疗方法。乙酰胆碱酯酶抑制剂（AChEI）治疗已显示出对阿尔茨海默病患者以及路易体痴呆、皮质下血管性痴呆和帕金森病等其他病症患者的认知功能有积极作用。在本文中，我们回顾了旨在证明AChEI可能是MS患者认知障碍潜在治疗方法的研究和临床试验结果。最后，我们讨论了在MS背景下AChEI治疗需考虑的未来问题。
